Prognostic implication of EGFR gene mutations and histological classification in patients with resected stage I lung adenocarcinoma

Chun-Yu Lin¹,²,³, Yen-Mu Wu⁴,⁵, Meng-Heng Hsieh²,³, Chih-Wei Wang³,⁶, Ching-Yang Wu³,⁷, Ying-Jen Chen¹,³, Yueh-Fu Fang²,³,⁸*

¹ Department of General Medicine & Geriatrics, Chang Gung Memorial Hospital at Linkou, Taoyuan, Taiwan, ² Department of Thoracic Medicine, Chang Gung Memorial Hospital at Linkou, Taoyuan, Taiwan, ³ College of Medicine Chang Gung University, Taoyuan, Taiwan, ⁴ Department of Infectious Diseases, Department of Internal Medicine, Chang Gung Memorial Hospital Linkou Medical Center, Taoyuan, Taiwan, ⁵ Graduate Institute of Clinical Medical Sciences, Chang Gung University, Taoyuan, Taiwan, ⁶ Department of Pathology, Chang Gung Memorial Hospital at Linkou, Taoyuan, Taiwan, ⁷ Department of Thoracic and Cardiovascular Surgery, Division of Surgery, Chang Gung Memorial Hospital, Linkou, Taiwan, ⁸ Department of Pulmonary and Critical Care, Saint Paul’s Hospital, Taoyuan, Taiwan

* dr.fang.yf@gmail.com

Abstract

Introduction

The prognostic value of epidermal growth factor receptor (EGFR) mutations and the correlation between EGFR mutations and the new International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society (IASLC/ATS/ERS) histological classification remain controversial. The current study aimed to investigate the pure prognostic role of EGFR mutations in treatment-naïve patients with resected stage I lung adenocarcinoma.

Methods

We retrospectively reviewed 373 patients with stage I pulmonary non-small-cell lung cancer who underwent complete surgical resection between January 2010 and May 2014. The tumors were classified according to IASLC/ATS/ERS criteria. EGFR mutation status was determined by established methods.

Results

A total of 120 patients were included for analysis; 87 had tumors with EGFR mutations and 33 had wild-type tumors. More low- and intermediate-grade tumors had EGFR mutations, and nearly half of the high-grade tumors were wild-type (75.7% versus 46.2%, p = 0.041). Patients with low-grade tumors had significantly greater median disease-free survival (DFS) (76.8 versus 13 months, p < 0.0001) and better overall survival (OS) (median OS not reached, p = 0.0003) than those with intermediate- and high-grade tumors. Tumor recurrence was 41.4% and 30.3% in mutant and wild-type patients. The 5-years survival rate was
54% and 71.2%. Multivariate analysis revealed that the new histological classification and the pathologic stage were independent predictors of both DFS and OS. EGFR mutation status had no prognostic implications.

Conclusion
Low grade tumors according to IASLC/ATS/ERS histological classification and the pathologic stage IA tumors of resected stage I lung adenocarcinomas independently predict better DFS and OS. EGFR mutations were frequently seen in histologically low- and intermediate-grade tumors but not a prognostic factor.

Introduction
Lung cancer is the major cause of cancer-related death worldwide [1]. Complete surgical resection remains the best curative treatment for patients with early-stage non-small-cell lung cancer (NSCLC) [2]. Several driver gene mutations are critical for cellular proliferation and survival, including epidermal growth factor receptor (EGFR), echinoderm microtubule-associated protein-like 4 (EML-4), and anaplastic lymphoma kinase (ALK) fusion, which are often highly susceptible to small-molecule tyrosine kinase inhibitors (TKIs) [3–5]. Patients with advanced NSCLC who harbored EGFR mutations consisting of deletion in exon 19 or the L858R mutation in exon 21 had a high response rate and prolonged survival after EGFR-TKI treatment [4, 6–8]. These results indicate that EGFR mutations are the major predictors of response to EGFR-TKI.

Unlike the predictive role of gene mutation in EGFR-TKI therapy, the prognostic value of EGFR mutation status has remained controversial, with conflicting results until now [9–22]. The outcome may not be appropriate in many studies of the prognostic implications of EGFR mutations because of the survival benefit of EGFR-TKI therapy in patients with EGFR mutant tumors. Patients with advanced EGFR mutant NSCLC may also have a better response to chemotherapy than those with wild-type tumors [23]. A new International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society (IASLC/ATS/ERS) histological classification has been validated with prognostic significance [24]. The correlations between genetic alteration and histological subtypes in lung adenocarcinoma remains controversial.

Considering the potential interference of perioperative therapy, the current study focuses on the pure prognostic impact of EGFR mutations in patients with resected stage I lung adenocarcinoma. We also investigate correlations between IASLC/ATS/ERS histological classification and EGFR mutation status [25].

Materials and methods
Patients
This retrospective study was approved by our institutional review board (201700457B0). The tissue specimens for genetic analysis were obtained with the patients’ consent. Between January 2010 and May 2014, a total of 373 patients with stage I pulmonary NSCLC underwent complete surgical resection at Linkou Chang Gung Memorial Hospital. Among them, 186 patients were tested for EGFR mutation status at the same time as routine pathologic review of the resected specimen. We excluded patients with stage II, III, or IV NSCLC; those who had
positive surgical margins, tumor histological findings other than adenocarcinoma, or absent or failed EGFR genotyping; and those who received neoadjuvant or adjuvant therapy. The final cohort consisted of 120 patients.

Histology and EGFR mutation analysis

The resected specimens were formalin-fixed and stained with hematoxylin and eosin in the conventional manner. Each tumor was reviewed using comprehensive histological subtyping by semiquantitatively estimating the percentages of the various subtypes present in 5% increments according to the IASLC/ATS/ERS classification [25]. The predominant pattern was defined as the pattern showing the greatest percentage, which was not necessarily 50% or greater. Each pulmonary adenocarcinoma subtype was further categorized as low-grade (adenocarcinoma in situ, minimal invasive adenocarcinoma, or lepidic predominant adenocarcinoma), intermediate-grade (acinar/papillary predominant adenocarcinoma), or high-grade (solid/micropapillary predominant, invasive mucinous adenocarcinoma) based on the prognosis [24, 26]. EGFR mutations were detected by direct DNA sequencing when the tumor purity was greater than 40%, and Scorpion amplification-refractory mutation system when the tumor purity was 5 to 40%. Competitive allele-specific TaqMan polymerase chain reaction was chosen when the tumor purity was below 5% [27]. EGFR mutations other than exon 19 deletion or exon 21 L858R mutation were categorized as rare mutations.

Covariates and data collection

Data on baseline patient characteristics were collected, including age, sex, smoking history, and Eastern Cooperative Oncology Group (ECOG) performance status. The date and type of surgery were recorded. Tumor stage was categorized according to the seventh edition of the American Joint Committee on Cancer guidelines for NSCLC [28]. After the operation, the patients were followed with chest X-rays every 3 months in the first year, every 6 months for the next 2 years, and yearly thereafter. Chest to abdomen computed tomography (CT) scans were obtained at least annually. Tumor recurrence was defined as radiographic evidence of cancer relapse on surveillance imaging, such as enlarging opacity at primary site, sequential enlarging opacity, bulging margin or loss of linear margin, etc. If possible, recurrences were confirmed pathologically. Disease-free survival (DFS) was defined as the time from initial surgery until tumor recurrence. Overall survival (OS) was defined as the time from initial surgery until death. The dates and causes of death were obtained from medical records.

Statistical analysis

The patients were divided into two groups, EGFR mutant and wild-type, based on the presence or absence of EGFR. Associations between clinical characteristics and recurrence rates were examined by Fisher’s exact test. DFS and OS were analyzed by the Kaplan—Meier method, and survival curves were compared by the log rank test. Independent prognostic factors for DFS and OS were determined by Cox multivariate analysis. Statistical significance was set at \( p < 0.05 \). The statistical analyses were performed with GraphPad Prism statistical software, version 6 (GraphPad Software, La Jolla, CA, USA) and IBM SPSS Statistics 20 for Mac (SPSS, Chicago, IL, USA).

Results

Patients

The characteristics of the 120 patients and their tumors are summarized in Table 1. There were more women (63.2% versus 30.3%, \( p = 0.002 \)) and never-smokers (81.6% versus 60.6%,...
Table 1. Demographics of patients and tumor characteristics.

| Variable                        | EGFR mutant | Wild-type | p Value |
|---------------------------------|-------------|-----------|---------|
| **Variable**                    | n = 87      | n = 33    |         |
| Age (y), mean ± SD              | 62.9 ± 1.3  | 64.2 ± 2.2| 0.60    |
| Sex, n (%)                      |             |           | 0.002   |
| Male                            | 32 (36.8)   | 23 (69.7) |         |
| Female                          | 55 (63.2)   | 10 (30.3) |         |
| Smoking, n (%)                  |             |           | 0.009   |
| Never                           | 71 (81.6)   | 20 (60.6) |         |
| Ever                            | 16 (18.4)   | 13 (39.4) |         |
| ECOG score, n (%)               |             | 1.0       |         |
| 0                               | 79 (90.8)   | 30 (90.9) |         |
| 1                               | 8 (9.2)     | 3 (9.1)   |         |
| Tumor size (cm), n (%)          |             |           | 0.30    |
| ≤ 2                             | 28 (32.2)   | 13 (39.4) |         |
| 2–3                             | 47 (54.0)   | 14 (42.4) |         |
| > 3                             | 12 (13.8)   | 6 (18.2)  |         |
| Pleural involvement, n (%)      |             | 0.64      |         |
| Invasion                        | 23 (26.4)   | 7 (21.2)  |         |
| Free                            | 64 (73.6)   | 26 (78.8) |         |
| Stage, n (%)                    |             | 0.83      |         |
| IA                              | 57 (65.5)   | 23 (69.7) |         |
| IB                              | 30 (34.5)   | 10 (30.3) |         |
| Histological classification, n (%)|           | 0.21      |         |
| Low-grade                       | 51 (58.6)   | 18 (54.5) |         |
| Adenocarcinoma in situ          | 0 (0)       | 2 (6.1)   |         |
| Lepidic                         | 51 (58.6)   | 16 (48.5) |         |
| Intermediate-grade              | 30 (34.5)   | 8 (24.2)  |         |
| Acinar                          | 26 (29.9)   | 5 (15.2)  |         |
| Papillary                       | 4 (4.6)     | 3 (9.1)   |         |
| High-grade                      | 6 (6.9)     | 7 (21.2)  |         |
| Micropapillary                  | 1 (1.1)     | 2 (6.1)   |         |
| Solid                           | 5 (5.7)     | 4 (12.1)  |         |
| Invasive mucinous               | 0 (0)       | 1 (3.0)   |         |
| EGFR mutation, n (%)            |             |           |         |
| Exon 19 deletion                | 31 (35.6)   |           |         |
| Exon 21 L858R                    | 52 (59.8)   |           |         |
| Rare mutation                   | 4 (4.6)     |           |         |
| Surgical procedure, n (%)       |             | 0.19      |         |
| Lobectomy                       | 75 (86.2)   | 27 (81.8) |         |
| Segmentectomy                   | 0 (0)       | 1 (3)     |         |
| Wedge resection                 | 12 (13.8)   | 5 (15.2)  |         |
| Recurrence, n (%)               | 36 (41.4)   | 10 (30.3) | 0.30    |
| Free, n (%)                     | 51 (58.6)   | 23 (69.7) |         |

ECOG, Eastern Cooperative Oncology Group; EGFR, epidermal growth factor receptor.

https://doi.org/10.1371/journal.pone.0186567.t001
p = 0.009) in the EGFR mutant group than in the wild-type group. Most patients (102 of 120 [85%]) underwent lobectomy, and the surgical procedures did not differ between the EGFR mutant group and the wild-type group. Half of the patients (67 of 120 [55.8%]) had lepidic predominant adenocarcinoma. More low- and intermediate-grade tumors than high-grade tumors had EGFR mutations (81 of 107 [75.7%] versus 6 of 13 [46.2%]; p = 0.041). More patients with lepidic predominant subtype (51 of 67 [76.1%]) or acinar subtype (26 of 31 [83.9%]) tumors had EGFR mutations than patients with wild-type tumors; however, the differences were not significant (p = 0.41 for lepidic subtype, p = 0.11 for acinar subtype).

**Genotype results**

Among the EGFR mutant group, 84 patients had a single mutation and 3 patients had double mutations. The most frequent EGFR mutations were the exon 21 point mutation L858R in 52 patients (59.8%) and the exon 19 deletion in 31 patients (35.6%). All of the three patients with double mutations had L858R. One of these patients had the exon 20 mutation T790M, one had R776H, and one had the exon 21 mutation K806I. The remaining four patients had rare mutations, including one patient with exon 20 insertion mutation, one with exon 20 deletion, one with exon 18 G724S, and one with exon 18 G719X.

**Analyses of disease-free survival and overall survival**

The median follow-up time was 46.7 months. Tumor recurrence was observed in 46 patients (36 [41.4%] in the EGFR mutant group and 10 [30.3%] in the wild-type group; p = 0.3). Four patients died of non-lung-cancer-related disease without tumor recurrence (two in the EGFR mutant group and two in the wild-type group). The median DFS was 76.8 months in the EGFR mutant group and was not reached in the wild-type group (p = 0.39) (Fig 1A, Table 2). Fifty-four percent of patients in the EGFR mutant group remained disease-free at 5 years, compared with 71.2% in the wild-type group. In the EGFR mutant subgroup analysis, patients harboring rare mutations had significantly shorter median DFS than those with exon 19 deletions or exon 21 L858R point mutations (17.85 months versus unreached in both the exon 19 and the exon 21 subgroups; p = 0.0033 and 0.0009, respectively) (Fig 1B). Univariate analysis revealed that pathologic stage IA and low-grade histological subtype were favorable prognostic factors for DFS (Table 2). The median DFS was 27.7 months in patients with stage IB tumors and was not reached in patients with stage IA tumors (p < 0.0001) (Fig 1C). DFS was significantly correlated with tumor histological classification (median DFS: 13 months in the high-grade, unreached in the intermediate-grade, and 76.8 months in the low-grade group; p < 0.0001) (Fig 1D). Sex, smoking status, types of surgical procedure and EGFR mutation status were not significant. Only pathologic stage (stage IA versus stage IB): hazard ratio [HR], 0.414; 95% confidence interval [CI], 0.223–0.955; p = 0.005) and tumor histological classification (low- versus intermediate- and high-grade: HR, 0.492; 95% CI, 0.262–0.917; p = 0.026) were independently significant predictors for DFS in the Cox proportional hazards model.

Treatment after disease recurrence is summarized in Table 3. Of the 36 patients in the EGFR mutant group with recurrence, 19 (52.8%) were treated with EGFR TKI, 15 (41.7%) received systemic chemotherapy, 7 (19.4%) underwent surgery, 3 (8.3%) received radiotherapy, and 2 (5.6%) received supportive care because of poor performance status. In the wild-type group, four patients (40%) were treated with EGFR TKI, five (50%) received systemic chemotherapy, two (20%) underwent surgery, one (10%) received radiotherapy, and one (10%) received immunotherapy.
There were 16 deaths, 13 in the EGFR mutant group and 3 in the wild-type group (p = 0.55). The median OS was unreached in both groups, and OS was comparable between groups (HR, 1.567; 95% CI, 0.4923–4.528; p = 0.4792). The estimated 5-year survival rate was 78% in the EGFR mutant group and 96.8% in the wild-type group (Fig 2A) (p = 0.48). Although the median OS was not reached, patients with stage IA tumor and those with low-grade adenocarcinomas had better OS (p = 0.0002, Fig 2B; p = 0.0003, Fig 2C). The prognostic value of sex, smoking status, types of surgical procedure and EGFR mutation status were not significant. In the Cox proportional hazards model, pathologic stage (stage IA versus stage IB: HR, 0.214; 95% CI, 0.058–0.788; p = 0.02) and histological classification (low- versus intermediate- and high-grade: HR, 0.151; 95% CI, 0.033–0.687; p = 0.015) were also independent prognostic factors for OS (Table 4).

**Discussion**

To our knowledge, this is the first study to focus on the prognostic difference by EGFR genotype and IASLC/ATS/ERS histological classification in resected stage I pulmonary adenocarcinoma. We investigated the outcomes in a cohort of 120 patients who had known EGFR mutation status and no perioperative therapy. We found that EGFR mutation status was

**Table 2. Cox proportional hazards model for analysis of disease-free survival.**

| Variable         | Category                        | Univariate analysis | Multivariate analysis |
|------------------|---------------------------------|---------------------|-----------------------|
|                  |                                 | HR                  | 95% CI                | P value   | HR                  | 95% CI                | P value   |
| Sex              | Male/female                     | 1.610               | 0.9061–2.917          | 0.1039    |                      |                      |           |
| Smoking          | Ever/never                      | 0.9400              | 0.4711–1.877          | 0.8622    |                      |                      |           |
| Surgical procedure | Lobectomy/Wedge resection      | 0.6326              | 0.2484–1.360          | 0.2123    | 0.489               | 0.230–1.041          | 0.064     |
| Pathologic stage | IA/IB                           | 0.3445              | 0.1433–0.511          | < 0.0001  | 0.382               | 0.206–0.709          | 0.002     |
| Histology        | Low/Intermediate, high          | 0.3923              | 0.196–0.668           | 0.0012    | 0.465               | 0.252–0.859          | 0.015     |
| EGFR mutation    | Mutant/wild                     | 1.353               | 0.6939–2.539          | 0.3941    |                      |                      |           |

CI, confidence interval; EGFR, epidermal growth factor receptor; HR, hazard ratio.
unrelated to DFS and OS. EGFR mutations were more frequent in patients with low- and intermediate-grade tumors. Pathologic stage and IASLC/ATS/ERS histological classification were independent prognostic factors for both DFS and OS in patients with resected stage I pulmonary adenocarcinoma.

There is accumulating evidence for a prognostic role of EGFR gene mutations in patients with resected NSCLC [9, 13, 14, 16, 20, 22, 29, 30]. However, many studies included patients with resected lung tumors in different stages and a variety of treatments. The lower risk of death in patients with EGFR mutations may be due to the survival benefit of EGFR-TKI therapy [16, 21]. Moreover, EGFR mutant tumors are more sensitive to chemotherapy than are wild-type tumors [23]. It is difficult to determine the outcome from disease biology or the benefit from perioperative therapy. The heterogeneity of treatment for recurrent disease may also

Table 3. Treatment modalities for recurrent disease.

| Therapy after recurrence | EGFR mutant n = 36 | Wild-type n = 10 |
|-------------------------|-------------------|-----------------|
| EGFR TKI, n (%)         | 19 (52.8)         | 4 (40)          |
| Chemotherapy, n (%)     | 15 (41.7)         | 5 (50)          |
| Surgery, n (%)          | 7 (19.4)          | 2 (20)          |
| Radiotherapy, n (%)     | 3 (8.3)           | 1 (10)          |
| Immunotherapy, n (%)    | 0 (0)             | 1 (10)          |
| Supportive care, n (%)  | 2 (5.6)           | 0 (0)           |

EGFR, epidermal growth factor receptor; TKI, tyrosine kinase inhibitor.

https://doi.org/10.1371/journal.pone.0186567.t003

Fig 2. Overall survival of patients with stage I resected pulmonary adenocarcinoma. (A) Overall survival in relation to EGFR mutation status. (B) Overall survival in relation to tumor pathologic stage. (C) Overall survival in relation to histological classification.

https://doi.org/10.1371/journal.pone.0186567.g002

Table 4. Cox proportional hazards model for analysis of overall survival.

| Variable          | Category                          | Univariate analysis | Multivariate analysis |
|-------------------|-----------------------------------|---------------------|----------------------|
|                   |                                   | HR                  | 95%CI                | P value  | HR                  | 95%CI                | P value  |
| Sex               | Male/female                       | 1.232               | 0.4608–3.307         | 0.6758   |                     |                     |          |
| Smoking           | Ever/never                        | 1.047               | 0.3334–3.291         | 0.9367   |                     |                     |          |
| Surgical procedure| Lobectomy/Wedge resection         | 3.019               | 0.5732–7.906         | 0.2598   | 1.934               | 0.248–15.088         | 0.529    |
| Pathologic stage  | IA/IB                             | 0.1413              | 0.050–0.3773         | 0.0002   | 0.222               | 0.060–0.824         | 0.024    |
| Histology         | Low/Intermediate, high            | 0.1008              | 0.0491–0.3894        | 0.0003   | 0.164               | 0.035–0.768         | 0.022    |
| EGFR mutation     | Mutant/wild                       | 1.567               | 0.4923–4.528         | 0.4792   |                     |                     |          |

CI, confidence interval; EGFR, epidermal growth factor receptor; HR, hazard ratio.

https://doi.org/10.1371/journal.pone.0186567.t004
affect OS [21]. DFS reflects the intrinsic biologic malignancy of EGFR mutation status. Thus, using DFS rather than OS and focusing on stage I patients who underwent resection without perioperative treatment is more appropriate for investigating the prognostic role of EGFR mutations. Five articles have focused on the prognostic implications of EGFR mutations in patients with resected stage I NSCLC [13, 14, 18, 20, 30].

Izar et al. found that patients with resected stage I, EGFR mutation-positive NSCLC without adjuvant therapy had significantly better DFS and OS than those with wild-type tumors [20]. Only 62 patients in the study had EGFR mutant tumors, and the other 245 patients had wild-type tumors because of the racial difference. In addition to EGFR mutations, KRAS gene mutations, which are responsible for NSCLC in 30% of white patients and 10%–15% of Asian patients, are also a prognostic factor [12, 31]. Among patients with resected stage I–III tumors, those with KRAS mutations had worse OS than those with EGFR mutations [15]. Another retrospective study of 312 patients with resected stage I lung adenocarcinoma conducted by Izar et al. showed that patients who had KRAS mutations had worse OS and DFS than patients who had EGFR mutations or were wild-type for both KRAS and EGFR [32]. In two Japanese studies, Ohba et al. found that patients with EGFR mutations and those with wild-type tumors had similar DFS and OS. KRAS mutations were the only independent prognostic factor in patients with resected stage I adenocarcinoma [13, 14]. In the Japanese studies, 41%–47% of patients had EGFR mutations and 5% had KRAS mutations. In contrast, in the study conducted by Izar et al [32], only 19% of patients had EGFR mutations and 40% had KRAS mutations. The conflicting results concerning the implication of EGFR mutations for prognosis may be due to the racial difference. Because of the very low prevalence of KRAS mutations in Taiwan, we did not test for KRAS mutations regularly [10, 30]. Nevertheless, similar to the findings of Ohba et al., we found no difference in DFS and OS between patients with EGFR mutant tumors and those with wild-type tumors.

Kobayashi et al. showed that tumor differentiation was the only independent factor for unfavorable OS and DFS [33]. They also found that the non-bronchioalveolar carcinoma component, but not EGFR mutation status, was strongly associated with poorer outcome [18]. The comprehensive lung adenocarcinoma classification proposed by IASLC/ATS/ERS in 2011 has significant implications for the prognostic role of tumor histology [24, 34]. Many studies have discussed the correlation between tumor gene mutations and histological classification. The strongest correlation between a histological subtype and a set of molecular and biologic features is that of invasive mucinous adenocarcinomas, which typically have KRAS mutations and lack EGFR mutations [25]. In one retrospective study of 410 patients with stage I lung adenocarcinoma, Isaka et al. showed that the EGFR exon 21 mutation was associated with low-grade adenocarcinoma with lepidic predominance, and that wild-type tumors were frequently high-grade tumors with vascular invasion [35]. In our study, we found that more low- and intermediate-grade tumors than high-grade tumors had EGFR mutations (81 of 107 [75.7%] versus 6 of 13 [46.2%]; p = 0.041). Moreover, the prognosis was strongly associated with tumor grade but not EGFR mutation status for both DFS and OS.

Accumulating evidence has validated the prognostic significance of the predominant histological subtype based on the IASLC/ATS/ERS classification rather than gene mutation status [34, 36–38]. Yoshizawa et al. reviewed 440 patients with resected lung adenocarcinomas and found that stage and histological grade were independent prognostic factors for both DFS and OS [38]. EGFR mutations were associated with low- to intermediate-grade adenocarcinomas, and KRAS mutations were associated with the mucinous subtype. However, in that study, KRAS mutations were not a prognostic factor for DFS and OS. Only EGFR mutations predicted a favorable 5-year survival rate, which could have been a benefit of EGFR-TKI treatment or adjuvant chemotherapy. We included only patients with completely resected stage I
lung adenocarcinoma who had never received perioperative treatment. Thus, we presented the biologically prognostic values of EGFR mutations and histological classification in patients with adenocarcinoma.

Our study has several inherent limitations. First, it was retrospective in design and conducted in a single center. There were 187 excluded patients who were not genotyped. Sixty-six patients were excluded because they had received perioperative treatment. Thus, the proportion of EGFR mutant tumors is somewhat higher in our study compared with general population in lung cancer patients. Second, the rule of EGFR mutation detection methods in our hospital is based on the tumor purity. Because the sensitivity of detection methods is different, this may somewhat interfere the outcome. Third, we only analyzed the outcome of patients with tumors harboring EGFR mutations and the relationship between EGFR mutations and histology. Because of the rarity of KRAS mutations in Taiwan, we did not investigate the potential influence of these mutations.

Conclusions
In summary, our study demonstrated that patients with stage IA tumor and those with low-grade tumors had better DFS and OS in patients with resected stage I lung adenocarcinoma who had no perioperative therapy. Although EGFR mutations were more frequently seen in patients with low- and intermediate-grade tumors, they had no prognostic implication. To investigate the prognostic role of driver mutations in lung adenocarcinomas and analyze the molecular correlations with histological subtypes, further prospective studies are warranted of larger numbers of patients, focusing on early-stage, resected lung cancer without perioperative treatment.

Supporting information
S1 Dataset.

Acknowledgments
We thank all the investigators and members of the Department of Thoracic Care Medicine and the Department of Internal Medicine at Chang Gung Memorial Hospital for their effort.

Author Contributions
Conceptualization: Chun-Yu Lin, Ching-Yang Wu, Yueh-Fu Fang.
Data curation: Chun-Yu Lin, Yueh-Fu Fang.
Formal analysis: Chun-Yu Lin.
Investigation: Chun-Yu Lin, Yen-Mu Wu, Meng-Heng Hsieh, Chih-Wei Wang, Ching-Yang Wu, Ying-Jen Chen, Yueh-Fu Fang.
Methodology: Chun-Yu Lin, Chih-Wei Wang, Ching-Yang Wu, Yueh-Fu Fang.
Project administration: Chun-Yu Lin.
Resources: Chun-Yu Lin, Ching-Yang Wu, Yueh-Fu Fang.
Supervision: Yueh-Fu Fang.
Validation: Chun-Yu Lin, Chih-Wei Wang, Ching-Yang Wu, Yueh-Fu Fang.
Writing – original draft: Chun-Yu Lin, Yen-Mu Wu, Meng-Heng Hsieh, Chih-Wei Wang, Ching-Yang Wu, Ying-Jen Chen, Yueh-Fu Fang.

Writing – review & editing: Chun-Yu Lin, Ching-Yang Wu, Yueh-Fu Fang.

References

1. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin. 2014; 64(1):9–29. https://doi.org/10.3322/caac.21208 PMID: 24399786.

2. Goldstraw P, Crowley J, Chansky K, Giroux DJ, Groom PA, Rami-Porta R, et al. The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours. J Thorac Oncol. 2007; 2(8):706–14. https://doi.org/10.1097/JTO.0b013e31812f3c1a PMID: 17762336.

3. Kwak EL, Bang YJ, Camidge DR, Shaw AT, Solomon B, Maki RG, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med. 2010; 363(18):1693–703. https://doi.org/10.1056/NEJMoa1006448 PMID: 2079469.

4. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 2004; 350(21):2129–39. https://doi.org/10.1056/NEJMoa0407936 PMID: 15118073.

5. Soda M, Choi YL, Enomoto M, Takada S, Yamashita Y, Ishikawa S, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature. 2007; 448(7153):561–6. https://doi.org/10.1038/nature05945 PMID: 17625570.

6. Takano T, Ohe Y, Sakamoto H, Tsuta K, Matsuno Y, Tateishi U, et al. Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer. J Clin Oncol. 2005; 23(28):6829–37. https://doi.org/10.1200/JCO.2005.01.0793 PMID: 15998907.

7. Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H, et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med. 2010; 362(25):2380–8. https://doi.org/10.1056/NEJMoa0909530 PMID: 20573926.

8. Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009; 361(10):947–57. https://doi.org/10.1056/NEJMoa0810699 PMID: 19692680.

9. Lee YJ, Park IK, Park MS, Choi HJ, Cho BC, Chung KY, et al. Activating mutations within the EGFR kinase domain: a molecular predictor of disease-free survival in resected pulmonary adenocarcinoma. J Cancer Res Clin Oncol. 2009; 135(12):1647–54. https://doi.org/10.1007/s00432-009-0611-7 PMID: 19517135.

10. Liu HP, Isaac Wu HD, Chang JW, Wu YC, Yang HY, Chen YT, et al. Prognostic implications of epidermal growth factor receptor and KRAS gene mutations and epidermal growth factor receptor gene copy numbers in patients with surgically resectable non-small cell lung cancer in Taiwan. J Thorac Oncol. 2010; 5(8):1175–84. https://doi.org/10.1097/JTO.0b013e3181e2f46 PMID: 20559151.

11. Liu WS, Zhao LJ, Pang GS, Yuan ZY, Li B, Wang P. Prognostic value of epidermal growth factor receptor mutations in resected lung adenocarcinomas. Med Oncol. 2014; 31(1):771. https://doi.org/10.1007/s12032-013-0771-9 PMID: 24248816.

12. Marks JL, Broderick S, Zhou Q, Chitale D, Li AR, Zakowski MF, et al. Prognostic and therapeutic implications of EGFR and KRAS mutations in resected lung adenocarcinoma. J Thorac Oncol. 2008; 3(2):111–6. https://doi.org/10.1097/JTO.0b013e3181b6e07 PMID: 18303429.

13. Ohba T, Toyokawa G, Kometani T, Nosaki K, Hirai F, Yamaguchi M, et al. Mutations of the EGFR and K-ras genes in resected stage I lung adenocarcinoma and their clinical significance. Surg Today. 2014; 44(3):478–86. https://doi.org/10.1007/s00595-013-0589-2 PMID: 23609009.

14. Ohba T, Toyokawa G, Osoegawa A, Hirai F, Yamaguchi M, Taguchi K, et al. Mutations of the EGFR, K-ras, EML4-ALK, and BRAF genes in resected pathological stage I lung adenocarcinoma. Surg Today. 2016; 46(9):1091–8. https://doi.org/10.1007/s00595-015-1295-z PMID: 26711128.

15. Sonobe M, Kobayashi M, Ishikawa M, Kikuchi R, Nakayama E, Takahashi T, et al. Impact of KRAS and EGFR gene mutations on recurrence and survival in patients with surgically resected lung adenocarcinomas. Ann Surg Oncol. 2012; 19 Suppl 3:S347–54. https://doi.org/10.1245/s10434-011-1799-8 PMID: 21607772.

16. D’Angelo SP, Janjigian YY, Ahye N, Riely GJ, Chaft JE, Sima CS, et al. Distinct clinical course of EGFR-mutant resected lung cancers: results of testing of 1118 surgical specimens and effects of...
Prognostic implication of EGFR gene mutations in stage I lung adenocarcinoma

adjuvant gefitinib and erlotinib. J Thorac Oncol. 2012; 7(12):1815–22. https://doi.org/10.1097/JTO.0b013e31826bb7b2 PMID: 23154553.

17. Kim YT, Seong YW, Jung YJ, Jeon YK, Park IK, Kang CH, et al. The presence of mutations in epidermal growth factor receptor gene is not a prognostic factor for long-term outcome after surgical resection of non-small-cell lung cancer. J Thorac Oncol. 2013; 8(2):171–8. PMID: 23287850.

18. Kobayashi N, Toyooka S, Ichimura K, Soh J, Yamamoto H, Matsuo K, et al. Non-BAC component but not epidermal growth factor receptor gene mutation is associated with poor outcomes in small adenocarcinoma of the lung. J Thorac Oncol. 2008; 3(7):704–10. https://doi.org/10.1097/JTO.0b013e1817c6080 PMID: 18594314.

19. Kosaka T, Yatabe Y, Onozato R, Kuwano H, Mitsudomi T. Prognostic implication of EGFR, KRAS, and TP53 gene mutations in a large cohort of Japanese patients with surgically treated lung adenocarcinoma. J Thorac Oncol. 2009; 4(1):22–9. https://doi.org/10.1097/JTO.0b013e1819141111 PMID: 19096302.

20. Izar B, Sequist L, Lee M, Muzikansky A, Heist R, Iafrate J, et al. The impact of EGFR mutation status on outcomes in patients with resected stage I non-small cell lung cancers. Ann Thorac Surg. 2013; 96(3):962–8. https://doi.org/10.1016/j.athoracsur.2013.05.091 PMID: 23932319.

21. Zhang Z, Wang T, Zhang J, Cai X, Pan C, Long Y, et al. Prognostic value of epidermal growth factor receptor mutations in resected non-small cell lung cancer: a systematic review with meta-analysis. PLoS One. 2014; 9(8):e106053. https://doi.org/10.1371/journal.pone.0106053 PMID: 25162713.

22. Nishi T, Yokose T, Miyagi Y, Daigo Y, Isaka T, Furumoto H, et al. Prognostic value of EGFR mutations in surgically resected pathological stage I lung adenocarcinoma. Asia Pac J Clin Oncol. 2016. https://doi.org/10.1111/ajco.12512 PMID: 27349355.

23. Zhang Q, Dai HH, Dong HY, Sun CT, Yang Z, Han JQ. EGFR mutations and clinical outcomes of chemotherapy for advanced non-small cell lung cancer: a meta-analysis. Lung Cancer. 2014; 85(3):339–46. https://doi.org/10.1016/j.lungcan.2014.06.011 PMID: 25043903.

24. Travis WD, Brambilla E, Nicholson AG, Yatabe Y, Austin JH, Beasley MB, et al. The 2015 World Health Organization Classification of Lung Tumors: Impact of Genetic, Clinical and Radiologic Advances Since the 2004 Classification. J Thorac Oncol. 2015; 10(9):1243–60. https://doi.org/10.1097/JTO.0000000000000630 PMID: 26291008.

25. Travis WD, Brambilla E, Noguchi M, Nicholson AG, Geisinger K, Yatabe Y, et al. International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society: international multidisciplinary classification of lung adenocarcinoma: executive summary. Proc Am Thorac Soc. 2011; 8(5):381–6. https://doi.org/10.1513/pats.201107-042ST PMID: 21926387.

26. Kadota K, Sima CS, Arcila ME, Hedvat C, Kris MG, Jones DR, et al. KRAS Mutation Is a Significant Prognostic Factor in Early-stage Lung Adenocarcinoma. Am J Surg Pathol. 2016; 40(12):1243–60. https://doi.org/10.1097/PAS.0000000000000744 PMID: 27740967.

27. Hsieh MH, Fang YF, Chang WC, Kuo HP, Lin SY, Liu HP, et al. Complex mutation patterns of epidermal growth factor receptor gene associated with variable responses to gefitinib treatment in patients with non-small cell lung cancer. Lung Cancer. 2006; 53(3):311–22. https://doi.org/10.1016/j.lungcan.2006.06.005 PMID: 16870303.

28. Chansky K, Sculier JP, Crowley JJ, Giroux D, Van Meerbeeck J, Goldstraw P, et al. The International Association for the Study of Lung Cancer Staging Project: prognostic factors and pathologic TNM stage in surgically managed non-small cell lung cancer. J Thorac Oncol. 2009; 4(7):792–801. https://doi.org/10.1097/JTO.0b013e3181a7716e PMID: 19458556.

29. Azzoli CG. Practical Value of Molecular Pathology in Stage I-III Lung Cancer: Implications for the Clinical Surgeon. Ann Surg Oncol. 2015; 22(11):3459–65. https://doi.org/10.1245/s10434-015-4704-z PMID: 26215190.

30. Yang CY, Lin MW, Chang YL, Wu CT, Yang PC. Programmed cell death-ligand 1 expression in surgically resected stage I pulmonary adenocarcinoma and its correlation with driver mutations and clinical outcomes. Eur J Cancer. 2014; 50(7):1361–9. https://doi.org/10.1016/j.ejca.2014.01.018 PMID: 24548766.

31. Mascaux C, Iannino N, Martin B, Paesmans M, Berghmans T, Dusart M, et al. The role of RAS oncogene in survival of patients with lung cancer: a systematic review of the literature with meta-analysis. Br J Cancer. 2005; 92(1):131–9. https://doi.org/10.1038/sj.bjc.6602258 PMID: 15597105.

32. Izar B, Zhou H, Heist RS, Azzoli CG, Muzikansky A, Scribner EE, et al. The prognostic impact of KRAS, its codon and amino acid specific mutations, on survival in resected stage I lung adenocarcinoma. J Thorac Oncol. 2014; 9(9):1363–9. https://doi.org/10.1097/JTO.000000000000266 PMID: 25122432.

33. Kobayashi N, Toyooka S, Soh J, Ichimura K, Yanai H, Suehisa H, et al. Risk factors for recurrence and unfavorable prognosis in patients with stage I non-small cell lung cancer and a tumor diameter of 20
mm or less. J Thorac Oncol. 2007; 2(9):808–12. https://doi.org/10.1097/JTO.0b013e31814617c7 PMID: 17805057.

34. Yoshizawa A, Motoi N, Riely GJ, Sima CS, Gerald WL, Kris MG, et al. Impact of proposed IASLC/ATS/ERS classification of lung adenocarcinoma: prognostic subgroups and implications for further revision of staging based on analysis of 514 stage I cases. Mod Pathol. 2011; 24(5):653–64. https://doi.org/10.1038/modpathol.2010.232 PMID: 21252858.

35. Isaka T, Yokose T, Ito H, Nagata M, Furumoto H, Nishii T, et al. Correlations Between the EGFR Mutation Status and Clinicopathological Features of Clinical Stage I Lung Adenocarcinoma. Medicine (Baltimore). 2015; 94(42):e1784. https://doi.org/10.1097/MD.0000000000001784 PMID: 26496308.

36. Mansuet-Lupo A, Bobbio A, Blons H, Becht E, Ouakrim H, Didelot A, et al. The new histologic classification of lung primary adenocarcinoma subtypes is a reliable prognostic marker and identifies tumors with different mutation status: the experience of a French cohort. Chest. 2014; 146(3):633–43. https://doi.org/10.1378/chest.13-2499 PMID: 24676429.

37. Nakamura H, Saji H, Shinmyo T, Tagaya R, Kurimoto N, Koizumi H, et al. Association of IASLC/ATS/ERS Histologic Subtypes of Lung Adenocarcinoma With Epidermal Growth Factor Receptor Mutations in 320 Resected Cases. Clin Lung Cancer. 2015; 16(3):209–15. https://doi.org/10.1016/j.cllc.2014.10.004 PMID: 25467929.

38. Yoshizawa A, Sumiyoshi S, Sonobe M, Kobayashi M, Fujimoto M, Kawakami F, et al. Validation of the IASLC/ATS/ERS lung adenocarcinoma classification for prognosis and association with EGFR and KRAS gene mutations: analysis of 440 Japanese patients. J Thorac Oncol. 2013; 8(1):52–61. https://doi.org/10.1097/JTO.0b013e31827e9a8 PMID: 23242438.